PALO ALTO, Calif. / Nov 01, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
● |
| Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA |
|
| Fireside chat on Tuesday, November 12 at 10:30 a.m. Eastern Time |
|
|
|
● |
| Wolfe Healthcare Conference in New York, NY |
|
| Hosting 1x1 meetings on Tuesday, November 19 |
|
|
|
● |
| Jefferies London Healthcare Conference 2024 in London, UK |
|
| Presentation on Wednesday, November 20 at 7:30 a.m. Greenwich Mean Time |
|
|
|
● |
| Piper Sandler Healthcare Conference in New York, NY |
|
| Fireside chat on Tuesday, December 3 at 8:30 a.m. Eastern Time |
Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn and X (Twitter).
| Last Trade: | US$44.97 |
| Daily Change: | -0.21 -0.46 |
| Daily Volume: | 1,795,323 |
| Market Cap: | US$5.560B |
February 20, 2025 January 30, 2025 January 21, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
